314 related articles for article (PubMed ID: 9328363)
1. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
Berns JS; Rudnick MR; Cohen RM
Clin Nephrol; 1992 May; 37(5):264-7. PubMed ID: 1606777
[TBL] [Abstract][Full Text] [Related]
3. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
[TBL] [Abstract][Full Text] [Related]
4. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
Navarro JF; Mora C; Macía M; García J
Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
[TBL] [Abstract][Full Text] [Related]
5. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients.
Barton Pai A; Chretien C; Lau AH
Clin Nephrol; 2002 Jul; 58(1):38-46. PubMed ID: 12141405
[TBL] [Abstract][Full Text] [Related]
6. Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin.
Lee MS; Ahn SH; Song JH
Korean J Intern Med; 2002 Sep; 17(3):167-73. PubMed ID: 12298427
[TBL] [Abstract][Full Text] [Related]
7. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis.
Gascón A; Belvis JJ; Berisa F; Iglesias E; Estopiñán V; Teruel JL
Geriatr Nephrol Urol; 1999; 9(2):67-72. PubMed ID: 10518249
[TBL] [Abstract][Full Text] [Related]
8. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis.
Sheashaa H; Abdel-Razek W; El-Husseini A; Selim A; Hassan N; Abbas T; El-Askalani H; Sobh M
Nephron Clin Pract; 2005; 99(4):c102-6. PubMed ID: 15703460
[TBL] [Abstract][Full Text] [Related]
9. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
10. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era.
Teruel JL; Aguilera A; Marcen R; Navarro Antolin J; Garcia Otero G; Ortuño J
Scand J Urol Nephrol; 1996 Oct; 30(5):403-8. PubMed ID: 8936631
[TBL] [Abstract][Full Text] [Related]
11. The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era.
Johansen KL
Int J Artif Organs; 2001 Apr; 24(4):183-5. PubMed ID: 11394696
[No Abstract] [Full Text] [Related]
12. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
13. Androgens for the anaemia of chronic kidney disease in adults.
Yang Q; Abudou M; Xie XS; Wu T
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006881. PubMed ID: 25300168
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
15. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
16. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study.
Teruel JL; Marcen R; Navarro-Antolin J; Aguilera A; Fernandez-Juarez G; Ortuño J
J Am Soc Nephrol; 1996 Jan; 7(1):140-4. PubMed ID: 8808121
[TBL] [Abstract][Full Text] [Related]
17. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis.
Belsha CW; Berry PL
Pediatr Nephrol; 1998 May; 12(4):298-303. PubMed ID: 9655362
[TBL] [Abstract][Full Text] [Related]
18. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
[TBL] [Abstract][Full Text] [Related]
19. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study.
Teruel JL; Marcén R; Navarro JF; Villafruela JJ; Fernández Lucas M; Liaño F; Ortuño J
Nephron; 1995; 70(3):282-6. PubMed ID: 7477614
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
